Immuron Limited - ADR
IMRN
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.6M
Close$
$-1.34
229.9% downside
Current Fair Value
229.9% downsideOvervalued by 229.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.60 Million |
|---|---|
| Enterprise Value | $2.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.5 |
| Beta | 0.51 |
| Outstanding Shares | 8,134,000 |
Return
| Return on Equity | -60.24% |
|---|---|
| Return on Assets | -51.03% |
| Return on Invested Capital | -68.03% |
Valuation & Multiples
| P/E Ratio | -3.49 |
|---|---|
| PEG | -8.54 |
| Price to Sales | 1.03 |
| Price to Book Ratio | 1.03 |
| Enterprise Value to Revenue | 0.23 |
| Enterprise Value to EBIT | -0.34 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-0.00
Average shareholder expectationRevenue Estimate
$2.75 M
Average shareholder expectationNext Earnings Call
Expected Date
February 19, 2027
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$3.36 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.05%▼ 0.19% |
|---|---|
| Total Invested | $82,217▲ 25.05% |
| Investors Holding | 6▼ 1.00% |
ESG Score
No data
About Immuron Limited
7 employees
CEO: Steven George Lydeamore Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Re...